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ABSTRACT
DNA methylation is an important regulator of gene function. Fetal sex is associated with the risk of several
speciﬁc pregnancy complications related to placental function. However, the association between fetal sex
and placental DNA methylation remains poorly understood. We carried out whole-genome oxidative bisulﬁte
sequencing in the placentas of two healthy female and two healthy male pregnancies generating an average
genome depth of coverage of 25x. Most highly ranked differentially methylated regions (DMRs) were located
on the X chromosome but we identiﬁed a 225 kb sex-speciﬁc DMR in the body of the CUB and Sushi Multiple
Domains 1 (CSMD1) gene on chromosome 8. The sex-speciﬁc differential methylation pattern observed in this
region was validated in additional placentas using in-solution target capture. In a new RNA-seq data set
from 64 female and 67 male placentas, CSMD1 mRNA was 1.8-fold higher in male than in female placentas
(P value = 8.5 £ 10¡7, Mann-Whitney test). Exon-level quantiﬁcation of CSMD1 mRNA from these 131
placentas suggested a likely placenta-speciﬁc CSMD1 isoform not detected in the 21 somatic tissues analyzed.
We show that the gene body of an autosomal gene, CSMD1, is differentially methylated in a sex- and










The placenta is a crucial, yet short-lived, organ at the interface
between mother and the developing fetus. Among its many
functions, it mediates nutrient uptake and gas and waste
exchange, and acts as protective barrier against some patho-
gens. Many adverse pregnancy outcomes, such as stillbirth,
neonatal death, growth restriction, cerebral palsy (due to oxy-
gen deprivation at birth), and preterm labor can be attributed
to compromised placental function [1]. Moreover, the intra-
uterine environment is also a key determinant of the risk for
cardiovascular disease in adult life [2]. Fetal sex is itself often
associated with increased risk for speciﬁc pregnancy complica-
tions [3] and, since the placenta is a fetal organ, it becomes a
suitable tissue to study the molecular mechanisms that may
underlie sex-speciﬁc adverse pregnancy outcomes.
DNA methylation is one of the most intensely studied
epigenetic regulatory mechanisms and determines cellular phe-
notypes, commonly through the regulation of transcript abun-
dance. Previous studies have demonstrated the role for DNA
methylation in placental genomic imprinting and X inactivation
[4-6]. Studies that applied whole-genome bisulﬁte sequencing to
analyze the placental methylome have either focused on
understanding genomic imprinting [7] or been limited to the
analysis of a single placenta [8] and could not, therefore, address
sex-speciﬁc patterns. Although a few studies have examined
sex-speciﬁc differences in DNA methylation, they have either
assayed DNA methylation for only 1–2% of CpG sites [9] or
speciﬁcally focused on X chromosome differences [4].
Given the vital role of the placenta in maintaining a healthy
pregnancy and the association between fetal sex and speciﬁc
pregnancy complications, we sought to characterize sex-speciﬁc
differences in global DNA methylation and identify sex-speciﬁc
differentially methylated regions from placental whole-genome
oxidative bisulﬁte sequencing data sets (WGoxBS). We tested
the hypothesis that sex-speciﬁc differential methylation is asso-
ciated with transcript abundance using an extensive placental
RNA-seq data set.
Results
Genome-wide methylation differences by fetal sex
We carried out whole-genome oxidative bisulﬁte sequencing
(WGoxBS) in two female and two male term placentas from
well-characterized healthy pregnancies of the Pregnancy
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Outcome Prediction Study Cohort [10-12] (Supplementary
Table S1). We obtained a total of 1.7 billion uniquely mapped
reads, this equates to an average of 26x genome coverage per
sample (Supplementary Table S2). For our initial analyses, we
used the 14,960,649 strand-speciﬁc CpG sites that were
sequenced at a depth of at least 10x and shared among all four
individuals (Supplementary Figure S1). As previously docu-
mented [8], the placenta has lower methylation levels than
other tissues, with a global CpG methylation value of 53.5%
(autosomes: 53.6%, X-chromosome: 46.6%). Methylation of
single CpG sites showed a typical bimodal distribution pattern
(Figure 1A), as previously reported [8,13], whereas CpG islands
(Figure 1D) were globally hypomethylated, as expected [14].
Gene bodies (Figure 1B) were the most methylated regions at
54%, followed by CpG island shores (47%), enhancers (35%),
promoters (20%) (Figure 1C), and CpG islands (16%). In addi-
tion to ﬁnding that male placentas were 1.6% more methylated
than female placentas, lowly methylated (<50%) single CpG
sites, gene bodies, and promoter regions were more common in
females (Figure 1A-1D). This global male-hypermethylation
was reproduced using an in-solution target capture methodol-
ogy (SureSelect) for the two samples assayed by WGoxBS (tech-
nical replicates; 1% more methylated in male). It was also
reproduced in six additional samples, three from female pla-
centas and three from male placentas (i.e., biological replicates;
1.5% more methylated in male) (Supplementary Table S3).
However, further investigation of eight other tissues from the
Schultz et al. [15] datasets suggests this male hypermethylation
could be tissue-speciﬁc, as female-hypermethylation is observed
in the adrenal and spleen (Supplementary Table S3).
Having observed global placental methylation differences
between the sexes, we investigated the chromosome-wide
methylation differences between females and males (Figure 2
and Supplementary Figure S3). Chromosome X CpGs were
globally hypomethylated in females, whereas there was little
evidence for sex-speciﬁc differences in overall methylation in
the autosomes (Figure 2). Next, we determined whether this
hypomethylation of the X chromosome in females varied
according to the genomic feature. We found that the X chro-
mosome was globally hypomethylated in females, except at
CpG islands, where females were hypermethylated compared
to males; this was also reproduced in the SureSelect datasets
(Supplementary Figure S4).
Sex-speciﬁc differentially methylated regions
In order to identify sex-speciﬁc differentially methylated
regions (DMRs), we analyzed our data using the Bioconductor
package RnBeads [16]. We created Manhattan plots analyzing
DMRs by 5 kb tiles, gene bodies, promoters, and CpG islands
(Figure 3A-3D). Consistent with the chromosome speciﬁc anal-
ysis of global methylation, most highly ranked DMRs were
located on the X chromosome (Supplementary Table S4). For
autosomal regions, apart from isolated regions with highly
Figure 1. Distribution of placental methylation level by fetal sex. The percentage methylation level was measured in autosomes separately from the chromosome X at (A)
single CpG sites, (B) gene-bodies, (C) promoters, and (D) CpG island regions. The distribution curves were plotted by the kernel density estimation, where the area under
the curve equals to one. The distributions of genome-wide methylation levels are shown in Supplementary Figure S2 and the methylation levels are described in Supple-
mentary Table S3.
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ranked sex-speciﬁc DMRs, there was strong evidence for a clus-
ter of multiple sex-speciﬁc DMRs located on chromosome 8
(Figure 3A).
The most highly ranked 5 kb DMR on chromosome 8 shows
average methylation values of 36% and 72% in females and
males, respectively. This DMR and 19 additional 5 kb DMRs
ranked amongst the top 100 differentially methylated regions
(Supplementary Table S4). All 20 DMRs were located within a
225 kb locus (8:2,795,000-3,020,000) of the CUB and Sushi
Multiple Domains 1 (CSMD1, 8:2,792,875-4,852,494) gene,
which is located on the minus strand (Figure 4). Consistent
with the highest ranked chromosome 8 DMR, the average
methylation value across these twenty 5 kb DMRs was 42% and
71% in females and males, respectively.
We then studied the CSMD1 and X chromosome DMRs
using SureSelect technical (n = 2) and biological replicates
(n = 6) (Supplementary Table S1). The in-solution target cap-
ture methodology yielded 2.4 and 1.3 million strand-speciﬁc
CpG sites that were sequenced at a depth of at least 10x and
shared among the two technical and six biological replicates,
respectively (Supplementary Table S5). We observed good con-
cordance (R2 = 0.81 females, R2 = 0.95 males) in the level of
methylation between technical and biological replicates of
X chromosome CpGs present in the 100 top-ranked 5 kb tile,
gene-body, promoter, and CpG island regions shown in
Figure 3A-3D (Supplementary Table S4 and Figure S5).
Females were consistently and signiﬁcantly hypomethylated
compared to males over the extensive differentially methylated
region of CSMD1 (Figure 4). With the in-solution target cap-
ture methodology, the level of methylation of individual CpG
sites within these 20 chromosome 8 DMRs was statistically
signiﬁcantly different between females and males, both for
the technical and biological replicates (P = 9.2 £ 10¡38 and
P = 1.1 £ 10¡29, respectively, Fisher’s Exact test). More
importantly, the average level of methylation within the chromo-
some 8 DMR in females and males (8:2,795,000-3,020,000) was
consistent among all three data sets: WGoxBS (47% vs. 71%,
n = 4), technical replicates (52% vs. 72%, n = 2), and biological
replicates (52% vs. 68%, n = 6). Having validated this extensive
sex-speciﬁc DMR, we then determined whether this sex-speciﬁc
methylation pattern is placenta-speciﬁc or observed in other tis-
sues. We obtained data from Schultz et al. [15] and studied the
same region in 8 somatic tissues, comparing methylation levels
in 1 male and 1 female. Interestingly, sex-speciﬁc differential
methylation of the CSMD1 region was only observed in the pla-
centa and not in the other 8 tissues studied (Supplementary
Figure S6). The average level of methylation in females and
males in these tissues was 82% and 81%, respectively. We also
examined the methylation proﬁle in 6 other tissues obtained
from the NIH Roadmap Epigenomics Mapping Consortium
[18]. Although only a single male [brain germinal matrix (87%),
hippocampus (89%), testis spermatozoa (84%)] and a single
female [fetal muscle (79%), fetal thymus (87%), breast luminal
epithelium (80%)] sample were available, no obvious male-
female methylation differences were observed. The 14 non-pla-
cental tissues were highly methylated at this locus (range: 79%
to 89%), regardless of the sex and the site where the bisulﬁte
sequencing data was generated (Supplementary Figure S6).
Sex-speciﬁc CSMD1 differential methylation and transcript
abundance
To understand the potential functional signiﬁcance of this
extensive and sex-speciﬁc differentially methylated region of
CSMD1 in the placenta, we quantiﬁed the abundance of
CSMD1 RNA from a placental RNA-seq data set generated
from 64 healthy female and 67 healthy male placentas (Supple-
mentary Tables S6 and S7). At the gene level, female samples
had 1.8-fold lower transcript abundance than male samples
(P = 8.5 £ 10¡7, Mann-Whitney test). As transcript abundance
typically is negatively correlated with the level of methylation
in the promoter [19], we compared the methylation level of the
annotated CSMD1 promoter region (8:4,851,994-4,853,994)
in female and male placental samples. We did not observe
sex-speciﬁc methylation differences at the promoter region
(Supplementary Figure S7). Intriguingly, we noted that most of
the placental RNA-seq reads aligned towards the 3’ end of the
CSMD1 gene, the same region where the 20 differentially meth-
ylated regions were identiﬁed (Figure 5). The ﬁrst canonical
exon [i.e., ﬁrst exon near the annotated transcription start site
(TSS), 8:4,851,994)] of CSMD1 did not have a single placental
RNA-seq read. This suggests that the CSMD1 placental tran-
script does not start with the canonical TSS.
Using RNA-seq data from 131 individual placentas, we
reconstructed the CSMD1 transcript. This showed that the ﬁrst
exon, and thus the TSS, is actually 1.8 mega base pairs down-
stream the canonical ﬁrst exon (Supplementary Figure S8).
This suggests that the placenta uses an alternative promoter
that is different from the reference gene annotation (e.g.,
GENCODE). Then, we re-examined the methylation level at
the likely promoter region (1,500 bp upstream and 500 bp
downstream the putative TSS) and found that females had
higher methylation values (38%) compared to males (23%)
Figure 2. Boxplot of methylation difference by fetal sex. The CpG methylation dif-
ferences were obtained from the percentage methylation level of females (n = 2)
subtracted by that of males (n = 2) at single CpG sites, gene-bodies, promoters,
and CpG island regions. The methylation differences were measured in autosomes
separately from the chromosome X. Each of the boxes shows the median and inter-
quartile range (IQR). The vertical lines (whiskers) extended from the box represent
a range of 1.5IQR from both ends. Data beyond the end of the whiskers (i.e., out-
liers) are not shown. Boxplots of chromosome-wide methylation difference are
shown in Supplementary Figure S3.
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in the WGoxBS data set (P = 1.7 £ 10¡13, Supplementary
Figure S9). This pattern of higher methylation in females was
also validated technically (38% vs. 29%) and biologically
(48% vs. 29%) using the in-solution target capture methodology
(P = 1.7 £ 10¡86 and P = 1.5 £ 10¡65, respectively, Fisher’s
Exact test, Supplementary Figure S9). In addition, the putative
promoter region is annotated as a DNase hypersensitive region,
a transcription factor binding site, and a transcription start site
(5' cap analysis gene expression, CAGE), which suggest the
putative promoter region is biologically relevant (Supplemen-
tary Figure S10). This region was hypermethylated (>79%) in
both sexes in all eight tissues from Schultz et al. (Supplemen-
tary Figure S11).
CSMD1 placenta-speciﬁc isoform
We further investigated whether this potential isoform of
CSMD1 is speciﬁc to the placenta. We obtained RNA-seq data
of ﬁve placenta-derived tissues from the NIH Roadmap Epige-
nomics Mapping Consortium (REMC) [18], 18 somatic tissues
from Schultz et al. [15], and three additional tissues from the
REMC, respectively (Supplementary Table S8). We quantiﬁed
CSMD1 mRNA abundance at the exon-level and compared the
placenta-related tissues, including our own data, with the other
21 tissues. All the placenta-derived tissues clustered separately
from the 21 non-placental tissues and they shared the same
exon (ENSE00002127078), which is the ﬁrst exon covered with
at least 8 uniquely mapped reads (Figure 6).
This is the candidate ﬁrst exon predicted as an alternative
transcript start site by the transcript reconstruction using our
131 RNA-seq samples. Interestingly, none of the other non-
placental tissues, except the cerebellum, have reads covering
this exon, suggesting that they do not use this putative ﬁrst
exon. We therefore propose that the placental transcript of
CSMD1 has a different TSS from other tissues and it is a novel
isoform speciﬁc to the placenta. The exon usage comparison
with other fetal and embryonic tissues [20] also supports this
putative TSS and a novel form of placenta CSMD1 transcript
(Supplementary Figure S12).
The putative protein encoded by the placental-speciﬁc tran-
script is predicted to contain 4 CUB and 18 Sushi extracellular
domains instead of the full 14 CUB and 28 Sushi domains,
as expected from the reference sequence (Supplementary
Figure S13). CSMD1 exon-level expression analysis from the
Figure 3. Manhattan plot of highly ranked sex-speciﬁc differentially methylated regions. Each dot represents a (A) a tile of 5 kb, (B) gene-body, (C) promoter, and (D) CpG
island region. Dots above the horizontal lines represent top 100 highly ranked DMRs within each ﬁgure. The green dots in (A) represent 20 top ranked DMRs within
CSMD1. The rank in Y-axis is converted from the combined rank of RnBeads (see Methods).
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Figure 4. Methylation proﬁles of the 3’ region of the CSMD1 locus. The ﬁgure focuses on the 3’ end of CSMD1, where the 20 differentially methylated 5 kb regions
(8:2,795,000-3,020,000) are located. The ﬁrst track shows the gene structure of CSMD1—the exons are represented by vertical lines and the introns by a horizontal line.
The second panel displays methylation proﬁles from the WGoxBS samples, where each dot represents one CpG site for each individual (male in orange and female in
green). The third panel shows the same samples analyzed by in-solution target capture. The fourth panel shows independent biological replicate samples analyzed using
in-solution capture. Placental WGoxBS samples show hypomethylation in females (green), which is technically and biologically validated using an in-solution target cap-
ture method. The ﬁgure is drawn using ggbio Bioconductor package [17].
Figure 5. Methylation proﬁles and RNA-seq coverage over the CSMD1 locus. The ﬁrst track displays the gene structure of the entire CSMD1 locus (8:2,792,875-4,852,494)
and the second panel shows the methylation proﬁle of the WGoxBS samples (n = 4), where each dot represents one CpG site for each individual. The third track displays
the mean RNA-seq coverage of 64 female and 67 male placental samples. Note that most of the RNA-seq reads are aligned toward the 3’ end, where the differentially
methylated regions are located (displayed in Figure 4). Canonical and placenta-speciﬁc transcription start sites are shown in blue and red, respectively.
EPIGENETICS 5
Figure 6. Hierarchical clustering of tissues based on the relative expression level of CSMD1 exons. Each column represents a tissue and each row represents an Ensembl
CSMD1 exon. The relative expression is measured in the log-scale of FPKM (see Methods) and it is colored from red (high) to dark blue (low). The columns (tissues) are
hierarchically clustered by the similarity of the expression pattern and the rows (exons) are ordered by the position of exons within the CSMD1 transcript: transcript-start
(top) to transcript-end (bottom). Except the placenta (this study), the RNA-Seq datasets of other tissues are from the following three participating members of NIH Road-
map Epigenomics Mapping Consortium: Schultz et al. (GEO accession: GSE16256), UCSF-UBC (GEO accession: GSE16368), and Broad Institute (GEO accession: GSE17312).
Exons that contain canonical and placenta-speciﬁc transcription start site (TSS) are shown in blue and red, respectively.
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64 female and 67 male placental RNA-seq data identiﬁed
15 exons that were signiﬁcantly differentially expressed
(P<0.05, Mann-Whitney test) in a sex-speciﬁc manner
(Supplementary Table S9). Consistent with the gene-level
quantiﬁcation, females showed lower expression compared
to males, from 14 exons out of the 15 signiﬁcantly differen-
tially expressed exons.
Discussion
Whole-genome oxidative bisulﬁte sequencing (WGoxBS) was
used as a discovery method to assay CpG methylation at single
nucleotide resolution in two female and two male healthy term
placentas with an average of 26x genome coverage per individ-
ual yielding a data set of »15 million CpGs (Supplementary
Table S2 and Supplementary Figure S1). The majority of meth-
ylation studies of the placenta have used Illumina BeadChip
arrays, which assay up to 450,000 CpGs, or have focused on
identifying differences between the placentas of healthy and
complicated pregnancies (reviewed by Bianco-Miotto et al.
[9]). As a discovery method, we carried out WGoxBS with vali-
dation in technical and biological replicates using in-solution
target capture bisulﬁte sequencing. Finally, using an RNA-seq
data set generated from 64 female and 67 male healthy term
placentas we determined gene- and exon-level transcript abun-
dance associated with a 225 kb sex-speciﬁc DMR located within
the CSMD1 gene.
In agreement with other studies, we showed that placental
DNA is hypomethylated compared to that from other somatic
tissues [4,21,22]. After examining the global methylation pro-
ﬁles within various genomic features, we observed that males
are generally hypermethylated compared to females, and the
differences are most evident on the X chromosome. There is an
exception, however, to this global male hypermethylation,
namely, X chromosome CpG islands hypermethylated in
females. Our own analysis of eight tissues from the whole-
genome bisulﬁte sequencing data of Schultz et al. showed that
X chromosome hypermethylation in CpG islands of females is
not unique to the placenta. Female hypermethylation of X
chromosome CpG island regions seems to be a common ﬁnd-
ing among different tissues, which was reported in a number of
other studies of X chromosome inactivation, DNA methylation
role at CpG island regions, and meta-analysis of human periph-
eral blood leukocytes [23-26].
Many (35) of our top 100 sex-speciﬁc 5 kb DMRs are on the
X chromosome. A similar observation was previous reported
by Youseﬁ et al. [27] The authors found, in umbilical cord
blood, that the majority (74%) of gender-associated signiﬁ-
cantly differentially methylated CpGs were located on the
X chromosome, with 64% of them being hypermethylated in
females. Also, a recent paper reports a similar observation [28].
Surprisingly, we found that 20 of the top 100 sex-speciﬁc 5 kb
DMRs were located within a 225 kb region of the gene-body of
CSMD1, with females being hypomethylated. The differential
methylation in this large region was not evident when analyz-
ing individual CpGs, CpG islands, or promoters. This suggests
that the use of 5 kb tiles alongside these other methods is able
to reveal additional chromosomal features that may be of func-
tional relevance. This also highlights the advantage of using
whole-genome analysis, as the number of CpGs evaluated is
higher (»30-fold in this study) than when using current array-
based methods. This observation was conﬁrmed using technical
and biological replicates. We did not observe sex-speciﬁc meth-
ylation of CSMD1 in any of the eight somatic tissues, which
suggests that this sex-speciﬁc differential methylation is
restricted. Demonstration of true placental speciﬁcity will
require systematic analysis of this CSMD1 DMR in all tissues
and developmental stages in replicate female and male samples.
Schultz et al. applied whole-genome bisulﬁte sequencing
(WGBS), a method in which 5-methylcytosine and 5-hydroxy-
methylcytosine are indistinguishable; therefore, the two modiﬁ-
cations are reported in aggregate [29,30]. As WGoxBS
measures 5-methylcytosine alone [31,32], we were able to
detect the CSMD1 DMR in the absence of 5-hydroxymethylcy-
tosine. Despite our discovery data set being derived from
WGoxBS, we technically validated our sex-speciﬁc CSMD1
DMR with an in-solution methodology using bisulﬁte conver-
sion alone. We also validated this observation in 3 additional
healthy female and male placentas (biological replicates) using
the same technique. Thus, we are conﬁdent that the placental
and sex-speciﬁc CSMD1 DMR is due to differences in 5-meth-
ylcytosine and not 5-hydroxymethylcytosine.
We analyzed CSMD1 RNA-seq reads obtained from 64
female and 67 male placental samples and showed a sex-speciﬁc
difference in transcript abundance, where females have lower
transcript abundance compared to males. Our analysis of tran-
script reconstruction based on the 131 placental RNA-seq sam-
ples suggests that the placenta may have a novel CSMD1
transcript that starts 1.8 mega base pairs downstream the
canonical ﬁrst exon. While no sex-speciﬁc methylation differ-
ences were detected in the canonical promoter, females had
higher methylation values in the newly identiﬁed putative pro-
moter region, which may explain overall decreased transcript
abundance in females when compared to males. This putative
placental promoter region was hypermethylated (>85%) in the
eight tissues from the Schulz et al. dataset with no evidence of
use of the putative ﬁrst placental exon. While sex-speciﬁc tran-
script abundance of CSMD1 can be explained by differences in
DNA methylation at the putative promoter region, the 225 kb
CSMD1 DMR, located 20 kb downstream the putative placen-
tal-speciﬁc ﬁrst exon, might also affect gene-level transcript
abundance.
Comparative analysis of RNA-seq data of CSMD1 at the
exon-level between the placenta-derived tissues and other adult
and fetal tissues indicates that the placenta has a different ﬁrst
exon and its location is consistent with our proposed model of
a novel transcript. The Ensembl genome browser annotates
that one of the CSMD1 transcripts (ENST00000520451) starts
with the same exon (ENSE00002127078), which we identiﬁed
as the putative ﬁrst exon in the placenta-derived tissues. How-
ever, the Ensembl transcript consists of only ﬁve exons with no
evidence of an open reading frame, whereas our model of a
novel placental CSMD1 transcript spans 35 exons and its pro-
tein-coding potential is highly marked by the Coding-Potential
Assessment Tool [33]. However, very little is known about the
possible function of CSMD1—it has neither a Gene Ontology
biological process nor a molecular function term associated
with it and the cellular components terms (“membrane” and
EPIGENETICS 7
“integral component of membrane”) are only inferred from
electronic annotation. Nonetheless, it has been linked in
genome-wide association studies with Parkinson’s disease,
Alzheimer’s disease, and schizophrenia (for an example see
[34]). A fragment of recombinant rat CSMD1 inhibited the
classical but not the alternative complement activation path-
ways [35]. A recent study showed that suppression of CSMD1
by short hairpin RNAs signiﬁcantly increased the proliferation,
cell migration, and invasiveness of MCF10A cells compared to
controls [36]. It is not known what possible role CSMD1 might
have in the placenta, but regulation of complement [37] and
cell invasiveness are known to be important [38].
The 225 kb DMR described above covers the exons (and
introns) that comprise this novel transcript, which is also dif-
ferentially expressed in male and female placentas. Gene body
methylation is an informative predictor of gene activity [39],
although detailed mechanistic understanding of this, and
particularly how it may differ between males and females, is
currently lacking.
Whole-genome oxidative bisulﬁte sequencing and in-solu-
tion target capture carried out in the placentas of healthy
female and male replicates allowed us to identify and validate a
sex-speciﬁc autosomal 225 kb differentially methylated region
in the CSMD1 gene which was hypermethylated in the male
placenta. RNA-seq analysis of 64 healthy female and 67 healthy
male placenta samples showed that CSMD1 had sex-speciﬁc
differential transcript abundance (»1.8-fold higher in male).
Analysis of DNA methylation and RNA-seq data from publi-
cally available data sets indicate that the differential methyla-
tion is likely to be placental-speciﬁc, with the presence of a
placental-speciﬁc CSMD1 isoform. Further studies will be
required to elucidate the cause, consequences, and role for sex-
speciﬁc differential methylation, transcript abundance, and pla-
cental-speciﬁc isoforms of CSMD1 in the placenta. These data
illustrate the beneﬁt of analyzing comprehensive RNA-seq data
in parallel with DNA methylation data.
Material and methods
Placental samples
All samples were obtained as part of The Pregnancy Outcome
Prediction study (POPs)—a prospective cohort study of nullip-
arous women attending the Rosie Hospital, Cambridge (UK).
The study and sample collection have been previously
described in detail [10-12]. Ethical approval for the study was
obtained by the Cambridgeshire 2 Research Ethics Committee
(reference number 07/H0308/163). All participants gave writ-
ten informed consent.
DNA extraction
Frozen placental tissue samples from four separate regions
from the basal plate of each term placenta were combined to
provide a single 20-24 mg sample for DNA extraction. This
was processed using the Qiagen DNeasy Blood & Tissue Kit
(Qiagen), according to the manufacturer’s instructions includ-
ing the RNase treatment. To achieve buffer compatibility for
oxidative whole-genome bisulﬁte conversion, placental DNA
was eluted in UltraPure water (Cambridge Epigenetix). All
DNA samples were quantiﬁed using the Qubit® dsDNA HS
Assay Kit (Life Technologies).
Whole-genome oxidative bisulﬁte sequencing
Placental genomic DNA (4 mg) from 4 healthy pregnancies was
processed to achieve 10 kb fragments with the g-Tube (Cova-
ris), according to the manufacturer’s instructions. Fragmented
DNA was concentrated using GeneJET puriﬁcation columns,
according to the manufacturer’s instructions (Thermo Fisher
Scientiﬁc). This fragmented and puriﬁed DNA (1.5 mg) was
taken forward for oxidation + bisulﬁte treatment using the
TrueMethyl Kit (Cambridge Epigenetix). The supplied
sequencing and digestion controls were added at least to 1%
(w/w) to the fragmented DNA. Buffer exchange, denaturation,
oxidation, bisulﬁte conversion, cleanup, and qualitative assess-
ment of 5-hydroxymethylcytosine oxidation was carried out
according to manufacturer’s instructions (version 3.1). Bisul-
ﬁte-converted DNA (50 ng) was used as input for library gener-
ation using the EpiGnomeTM Methyl-Seq Kit (Epicentre) and
EpiGnomeTM Index PCR Primers (Epicentre), according to
manufacturer’s instructions. All double and single stranded
DNA was quantiﬁed using the Qubit dsDNA HS Assay Kit and
Qubit ssDNA Assay Kits, respectively, according to the manu-
facturer’s instructions (Life Technologies), and were sized with
the Agilent Bioanalyzer 2100 High Sensitivity DNA assay.
Molarity of each of the libraries was determined by qPCR using
the KAPA Illumina ABI Prism Library Quantiﬁcation Kit
(Kapa Biosystems). Indexed libraries were pooled at an equi-
molar ratio. To increase the number of uniquely sequenced
reads, two independent libraries were generated for each indi-
vidual. Multiplexed sequencing was carried out on the Illumina
MiSeq, HiSeq 2000, and HiSeq 2500 instruments with 2 £ 100,
2 £ 150 and 2 £ 125 cycles using MiSeq Reagent Kit v3, HiSeq
SBS Kit v3 and HiSeq SBS Kit v4, respectively. The methylation
conversion rate of the supplied sequencing controls was
checked with bsExpress (https://bitbucket.org/cegx-bfx/cegx_b
sexpress_docker).
In-solution target capture library preparation and
sequencing
Placental genomic DNA (3.5 mg) from 8 healthy pregnancies
(including 2 from the WGoxBS) was fragmented by the Covaris
S220 system according to the SureSelect Methyl-Seq target
enrichment protocol (Agilent). As oxidative bisulﬁte sequenc-
ing was unsupported, library preparation, hybridization, bisul-
ﬁte conversion, indexing, and sample pooling were carried out
according to manufacturer’s instructions. After the 3’ end
adenylation step, we excluded DNA fragments >500 bases by
performing an AMPure XP bead selection with a 0.6x bead to
DNA ratio discarding the larger fragments that were bound by
the beads. We continued the prescribed puriﬁcation by adding
an additional 1.2x volume beads to the supernatant to bring the
ﬁnal ratio to 1.8x. Resultant libraries were sized with the Agi-
lent Bioanalyzer 2100 High Sensitivity DNA assay and molarity
of each library was determined by qPCR using the KAPA Illu-
mina ABI Prism Library Quantiﬁcation Kit (Kapa Biosystems).
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All 8 libraries were pooled and sequenced on the Illumina
HiSeq 2500 instrument with 2 £ 125 cycles using HiSeq SBS
Kit v4 and a single lane of the Illumina HiSeq 4000 instrument
with 2 £ 150 cycles using HiSeq 3000/4000 SBS Kit following
Illumina’s guidelines (Illumina Application Note: Epigenetics
February 2016).
Placental biopsies and RNA extraction
Placental biopsies (n = 64 female placentas, n = 67 male pla-
centas) were selected from healthy pregnancies from the POPs
cohort. These patients had no evidence of hypertension at
booking and during pregnancy, did not experience pre-eclamp-
sia, Hemolysis, Elevated Liver enzymes, and Low Platelets
(HELLP) syndrome, gestational diabetes, or diabetes mellitus
type I or type II and other obstetric complications. They deliv-
ered live babies with a birth weight percentile in the normal
range (20-80th percentile), with no evidence of slowing in fetal
growth trajectory. Chorionic villi from the corresponding
placentas (free from decidua, visible infarction, calciﬁcation,
hematoma, or damage) were collected and processed within
30 minutes of separation from the uterus. After repeated
washes in chilled phosphate buffered saline, the samples were
placed in RNA later (Applied Biosystems) and stored at -80C.
Total placental RNA was extracted using mirVana Isolation Kit
(Ambion). For each placenta, approximately 5 mg of tissue
were homogenized in the Lysis/Binding solution for 20 sec at
6 m/s using a bead beater (FastPrep24) and Lysing Matrix D
Tubes (MP Biomedicals). The samples were then spun at
13,000 rpm for 5 min at 4C and the supernatants recovered.
Afterwards, the manufacturer’s instructions were followed.
Immediately after the RNA extraction, placental RNA samples
were DNase-treated using DNA-free DNA Removal Kit
(Ambion), aliquoted, and stored in -80C. Quantity and quality
of the RNA samples were assessed using the Agilent 2100 Bioa-
nalyzer, the Agilent RNA 6000 Nano Kit (Agilent Technolo-
gies), and Qubit ﬂuorometer.
Library preparation for RNA-Seq
Libraries were prepared starting with 300-500 ng of good qual-
ity total RNA (RIN 7.5) using the TruSeq Stranded Total
RNA Library Prep Kit with Ribo-Zero Human/Mouse/Rat
(Illumina), according to the manufacturer’s instructions. The
kit contains 96 uniquely indexed adapter combinations in order
to allow pooling of multiple samples prior to sequencing. After
determining their size (with the Agilent 2100 Bioanalyzer and
the Agilent High Sensitivity DNA Kit by Agilent Technologies)
and concentration (by qPCR with the KAPA Illumina ABI
Prism Library Quantiﬁcation Kit, Kapa Biosystems), libraries
have been pooled and sequenced (single-end, 125 bp) using a
Single End V4 Cluster Kit and an Illumina HiSeq2500 or
HiSeq4000 instrument.
Sequencing data processing and analysis
Both WGoxBS and in-solution target capture data went
through the quality control process (i.e., trimming primer
sequences and poor quality bases toward 3’ end) by Trim
Galore! [40] after checking the quality metrics of raw reads
with FastQC [41]. Then, the high quality trimmed reads were
mapped to the human genome reference (hg19) using Bismark
[42]. Reads of poor mapping quality (MAPQ = 0) and dupli-
cated reads (i.e., those mapped at the same start and end posi-
tion within the same chromosome) were removed from the
alignment ﬁles before calling methylated CpGs by Bis-SNP
[43], which is a genotype-aware methylcytosine caller enabled
with a base-quality recalibration function built on top of the
Genome Analysis Toolkit [44]. The VCF ﬁles generated by
Bis-SNP were converted into BED format as inputs for
RnBeads [16] to ﬁnd differentially methylated regions.
RnBeads considers both the statistical signiﬁcance (i.e.,
P value) and the effect size (i.e., absolute and relative methyla-
tion difference) and takes the worst rank (combined rank)
from the three individual ranks of aforementioned measure-
ments. In Manhattan plots (Figure 3), to make highly ranked
DMRs (smaller values) appear in top, the original combined
rank is converted by subtracting the log-scale of combined
rank from the log-scale of maximum rank. CpGs of at least
10x coverage and shared among all four individuals were con-
sidered and DMRs were ﬁltered if they had fewer CpG sites
compared to the median of the CpGs found in the dataset: 17
(5 kb tiles), 61 (gene-bodies), 18 (promoters), and 51 (CpG
islands).
The deﬁnitions of CpG island regions and the gene model
were from the UCSC (hg19) table browser [45] and the
Ensembl 73 equivalent with the GENCODE version 18, respec-
tively, which were accompanied with RnBeads package. The
promoter regions were deﬁned as 1,500 bp upstream and
500 bp downstream regions of the transcription start sites. The
CpG island shore regions were deﬁned as 2,000 bp ﬂanking
regions from both ends of the CpG island regions. The
‘5,000bp’ regions (5 kb) are deﬁned as a set of genomic regions
where each chromosome is tiled by non-overlapping 5 kb
windows.
Technical and biological validation of the sex-speciﬁc meth-
ylation patterns was performed using Fisher’s exact test on a
2 £ 2 contingency table by testing independence of sex and the
cumulative count of methylated CpGs over the 5,000 bp region.
For technical validation, one female and one male sample were
tested by both WGoxBS and in-solution capture methodolo-
gies. For biological validation, all 3 female and all 3 male
samples assayed by the in-solution capture methodology were
used. A two-sided P value <0.05 was considered statistically
signiﬁcant.
The Schultz et al. [15] methylation data for 8 tissues [adrenal
gland (AD), aorta (AO), esophagus (EG), adipose tissue (FT),
gastric (GA), psoas muscle (PO), small bowel (SB), and spleen
(SX)] were downloaded from http://neomorph.salk.edu/SDEC_
tissue_methylomes/processed_data/allc_tissues.tar. CpGs with
at least 10x coverage detected in individual 2 (a female) and
individual 3 (a male) were used. The cytosine methylation level
was measured as recommended by Schultz et al. [46]. Brieﬂy,
for single CpG sites, the ratio of reads with methylation
(C base) out of the total number of reads covering the position
(sum of C and T reads) was calculated; within regional contexts
(e.g., gene-body, CpG island, promoter, etc.), the weighted
methylation level (i.e., the sum of reads with methylation out of
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the sum of the total number reads over the region of interest)
was determined. Other Roadmap [18] whole-genome bisulﬁte
sequencing datasets generated at the Broad Institute and
UCSF-UBC were downloaded from the GEO website (https://
www.ncbi.nlm.nih.gov/geo/roadmap/epigenomics), as follows:
fetal muscle (fMU, GSM1172596); fetal thymus (fMU,
GSM1172595); hippocampus (HC, GSM1112838 and
GSM916050); brain germinal matrix (GM, GSM941747); breast
luminal epithelial (LE, GSM1127125), and testis spermatozoa
(SP, GSM1127117). The list of tissues and downloaded ﬁle
names are available in Supplementary Table S8.
A quality control process was also applied for the RNA-Seq
datasets: reads were trimmed with Trim Galore!, which uses
cutadapt internally [47] and were mapped to the same version
of human genome reference (hg19). TopHat2 [48], a splice-
aware mapper built on top of Bowtie2 [49] short-read aligner,
was used in the mapping process in which so-called two-pass
(or two-scan) alignment protocol was applied to rescue
unmapped reads from the initial mapping step [50]. In the
second mapping, previously unmapped reads were re-aligned
to the exon-intron junctions detected in the ﬁrst-mapping by
TopHat2 and were combined across all 131 placenta samples.
The initial and second mapped reads were merged by sam-
tools [51] and the uniquely mapped reads were counted by
the htseq-count of HTSeq [52] against the same gene-model
(Ensembl 73) used to calculate the degree of methylation at
the gene-body or promoter region. The transcript abundance
of CSMD1 was measured in fragments per kilobase of tran-
script per million (FPKM) mapped reads using DESeq2 Bio-
conductor package [53]. The average depth of RNA-seq
coverage was measured by taking the mean of each coverage
calculated by the ‘genomecov’ of Bedtools [54]. The exon-level
expression of CSMD1 was measured by counting mapped
reads against 98 unique exons (i.e., Ensembl exons with a dis-
tinct start and end position) of CSMD1 using featureCount of
subRead [50] and ‘coverageBed’ of Bedtools. The exon-level
FPKM values were transformed by the following equation:
loge(FPKM/1000+1) and used to generate the heatmap
(Figure 6). The CSMD1 transcripts were reconstructed based
on the RNA-seq data obtained from the 131 placenta samples
using StringTie [55] and Cufﬂinks [56]. The RNA-seq data
from Schultz et al. [15] and two other participating institutes
from the NIH Roadmap consortium (UCSF-UCB and The
Broad Institute) were downloaded from the GEO with the fol-
lowing accession numbers: GSE16256 (Schultz et al.),
GSE16368 (UCSF-UCB), and GSE17312 (Broad Institute).
The list of tissues and downloaded ﬁle names are provided in
Supplementary Table S8.
The summary statistics (read counts, coverage, mapping efﬁ-
ciencies, etc.) of the data processing for the WGoxBS, in-solu-
tion target capture methyl-Seq, and RNA-Seq data are available
in Supplementary Table S2, Supplementary Table S5, and Sup-
plementary Table S7, respectively. A list of software, version
information, and non-default options used in this study is
available in Supplementary Table S10. All the computational
analyses were conducted using the Linux clusters at the Univer-
sity of Cambridge High Performance Computing Service and
the Linux workstations of School of Biological Science comput-
ing service.
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